**RESEARCH ARTICLE**

**LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis**

Zhengyu Jiang¹,⁵, Carolyn M. Slater¹, Yan Zhou², Karthik Devarajan², Karen J. Ruth², Yueran Li¹,⁶, Kathy Q. Cai³, Mary Daly⁴ and Xiaowei Chen¹*  

**Abstract**

**Background:** Recent genome-wide profiling by sequencing and distinctive chromatin signatures has identified thousands of long non-coding RNA (lncRNA) species (>200 nt). LncRNAs have emerged as important regulators of gene expression, involving in both developmental and pathological processes. While altered expression of lncRNAs has been observed in breast cancer development, their roles in breast cancer progression and metastasis are still poorly understood.

**Methods:** To identify novel breast cancer-associated lncRNA candidates, we employed a high-density SNP array-based approach to uncover intergenic lncRNA genes that are aberrantly expressed in breast cancer. We first evaluated the potential value as a breast cancer prognostic biomarker for one breast cancer-associated lncRNA, LincIN, using a breast cancer cohort retrieved from The Cancer Genome Atlas (TCGA) Data Portal. Then we characterized the role of LincIN in breast cancer progression and metastasis by in vitro invasion assay and a mouse tail vein injection metastasis model. To study the action of LincIN, we identified LincIN-interacting protein partner(s) by RNA pull-down experiments followed with protein identification by mass spectrometry.

**Results:** High levels of LincIN expression are frequently observed in tumors compared to adjacent normal tissues, and are strongly associated with aggressive breast cancer. Importantly, analysis of TCGA data further suggest that high expression of LincIN is associated with poor overall survival in patients with breast cancer ($P = 0.044$ and $P = 0.011$ after adjustment for age). The functional experiments demonstrate that knockdown of LincIN inhibits tumor cell migration and invasion in vitro, which is supported by the results of transcriptome analysis in the LincIN-knockdown cells. Furthermore, knockdown of LincIN diminishes lung metastasis in a mouse tail vein injection model. We also identified a LincIN-binding protein, NF90, through which overexpression of LincIN may repress p21 protein expression by inhibiting its translation, and upregulation of p21 by LincIN knockdown may be associated with less aggressive metastasis phenotypes.

**Conclusions:** Our studies provide clear evidence to support LincIN as a new regulator of tumor progression-metastasis at both transcriptional and translational levels and as a promising prognostic biomarker for breast cancer.

**Keywords:** lncRNA, LincIN, NF90, Metastasis, Breast cancer

* Correspondence: Xiaowei.Chen@fccc.edu  
¹Cancer Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA  
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Genome-wide profiling by deep sequencing and mapping distinctive chromatin signatures have identified thousands of long non-coding ribonucleic acid (lncRNA) species (>200 nt in length) [1–3]. A majority of these lncRNAs are derived from the intergenic genome and used to be considered as “transcriptional noise”. Now, some lncRNAs are recognized as novel regulators of gene expression, involving in both developmental and pathological processes [4–6]. Considerable attention has been garnered for the roles of lncRNAs in the development of cancer. Several well-characterized lncRNAs, such as HOTAIR, FALI, NKILA, LSINCT5, and BCAR4, exhibit aberrant expression in cancer tissues and are associated with tumor progression and/or metastasis [7–11]. Hence, abnormal expression levels of these lncRNAs have potential clinical values as prognostic biomarkers, in addition to functional roles in promoting cancer [12]. In contrast to regulatory microRNAs, the functions of lncRNAs are not simply defined by a common mode of action, and each of them can act in a number of different ways, such as signals, decoys, guides or scaffolds [13]. In the nucleus, lncRNAs are primarily known for their interaction with chromatin modifiers, transcription factors or co-regulators, and DNA methylation enzymes, and, thus, epigenetically controlling gene transcription [14–16]. When present in the cytoplasm, lncRNAs are capable of regulating a number of post-transcriptional, translational and post-translational processes [17–19]. For example, the Half-staufen 1-binding site IncRNA (1/2bssRNAs) is involved in staufen 1-mediated mRNA decay [18]. NORAD maintains genomic stability by sequestering PUMILIO proteins and regulates targeted mRNA stability and translation [19]. LincRNA-p21 coordinates with RNA-binding protein HuR in the cytoplasm and modulates mRNA translation [20]. LncRNAs have also been found to directly regulate signal transduction at the post-translational level [9, 21]. For example, Lnc-DC expressed by dendritic cells promotes STAT6 phosphorylation and the activation of STAT6 signaling [21]. Although dysregulation of IncRNAs has been increasingly appreciated as a new “hallmark” of human cancer [22], the functional roles and regulatory mechanisms of many lncRNAs remain largely unknown, particularly for their co-actions with binding protein partners in these processes.

Nuclear factor 90 (NF90), a major spliced form of interleukin enhancer binding factor 3 (ILF3), was first identified on the basis of its ability to bind to the IL2 promoter in activated T cells [23], and it was subsequently found to bind double-stranded (ds) RNA structural elements [24]. Recent studies have shown that NF90 forms a complex with NF45 and plays multifunctional roles in the cells, including transcription, and microRNA biogenesis [25]. In addition to modulating transcription, NF90 is also capable of regulating gene expression at the post-transcriptional and translational levels [26–29]. However, the precise function of NF90 remains to be uncovered.

In the current investigation, we identified and characterized a novel breast cancer metastasis-associated IncRNA, a long intergenic non-coding RNA between ITGB1 and NRP1 (LincIN), by utilizing a high-density SNP array-based gene expression approach to evaluate the lncRNA transcriptome in paired normal versus tumor samples. LincIN is elevated in the majority of breast tumors and high levels of LincIN expression predict poor clinical outcomes. Our functional studies showed that LincIN plays a key role in breast cancer cell invasion and metastasis, interacts with NF90, and appears to regulate p21 expression at the translation level. Altogether, our studies provide evidence to support LincIN as a regulator in tumor cell invasion and a promising prognostic biomarker for breast cancer.

Methods

Bio specimens and a TCGA breast cancer cohort

Primary human mammary epithelial cells (HMECs) from breast tumors and matched adjacent non-tumor tissues were isolated and cultured as previously described [30]. For evaluating the expression of LincIN in clinical specimens by in situ analysis, a breast cancer tissue microarray (TMA) was prepared by the Biosample Core Facility of Fox Chase Cancer Center (FCCC). In addition, RNaseq reads per kilobase million (RPKM) values at the LincIN locus (reads falling into: chr10:3360887-3361048) as well as clinical and follow-up information were downloaded from The Cancer Genome Atlas (TCGA) Data Portal (https://tcga-data.nci.nih.gov) [31].
Quantitative RT-PCR (RT-qPCR)

Quantitative PCR (qPCR) was performed using the ABI 7900HT system (Applied Biosystems, Foster City, CA, USA). TaqMan assays for p21<sup>WAF1</sup>, LincIN, and GAPDH were designed and purchased from Applied Biosystems. In addition, the qPCR amplicon for each gene was cloned into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA, USA). Linearized plasmids carrying respective gene amplicons were diluted and used for constructing standard curves for each gene. All cDNA samples calculated from 20 ng of total RNA per reaction were assayed in quadruplicate in 384 microwell plates.

Microarray

Total RNA was isolated using TRIzol reagent (Invitrogen) and the quality of total RNA was assessed by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). A total of 250 ng of total RNA sample was labeled and hybridized to the Affymetrix Human Gene 2.0 ST Array according to the manufacturer’s instructions. Linearized plasmids carrying respective gene amplicons were designed and purchased from Applied Biosystems. In addition, the qPCR amplicon for each gene was cloned into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA, USA). Linearized plasmids carrying respective gene amplicons were diluted and used for constructing standard curves for each gene. All cDNA samples calculated from 20 ng of total RNA per reaction were assayed in quadruplicate in 384 microwell plates.

RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE)

5’ and 3’ RLM-RACE analysis was performed using the FirstChoice™ RLM-RACE Kit (Life Technologies, Carlsbad, CA, USA) as previously described [30]. For the 5’ end, first internal and nested primer sequences were as follows, ATTTAATAACGATGATTTATTTTCCTCACAC and AGAACCTCGCCCTCTCCCTGTG. For the 3’ end, internal and nested primer sequences were as follows, AGCAAAACCTGAAGCCCAAGAG and AATTCCCCATGGAGGAAAGAG.

RNA in situ hybridization (ISH)

RNA ISH was performed with the RNAscope<sup>™</sup> 2.0 HD formalin-fixed, paraffin-embedded (FFPE) Assay Kits [Advanced Cell Diagnostics (ACD), Newark, CA, USA] following the manufacturer’s user manual. LincIN- specific RNA probes were custom designed by ACD. RNA staining of individual cells was scored semi-quantitatively according to the manufacturer’s instructions with minor modifications. Briefly, the expression levels of LincIN, dapB (negative control) and POLR2 (positive control) were scored manually by two independent observers using the slightly modified guidelines recommended by ACD: 0 (no staining or <1 dot/10 cell), 1 (1–10 dots/cell and few dot clusters) and 2 (>10 dots/cell and >10% of dots are in clusters).

Cell lines

Non-tumorigenic mammary epithelial cell lines, MCF-10A and -10F, and human breast cancer cell lines, BT-20, HCC-1937, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1, were purchased from American Type Culture Collection (ATCC). Cell lines were maintained according to ATCC recommended medium at 37 °C in the presence of 5% CO<sub>2</sub>. MDA-MB-231Luc was gifted by Dr. Jose Russo (FCCC). MCF10ADCIS and SUM225 cells were gifts from Dr. Fariba Behbod (University of Kansas Medical Center) and were maintained as previously described [33].

Antibodies

The following primary antibodies were used: NF90 rabbit polyclonal antibody (1:10000, Cat# ab131004, Abcam, Cambridge, MA, USA), NF45 rabbit monoclonal antibody (1:1000, Cat# ab31004, Abcam), p21<sup>WAF1</sup> mouse monoclonal antibody (1:200, Cat# OP64, Calbiochem, La Jolla, CA, USA), Keratin rabbit monoclonal antibody (1:1000, Cat# ab8068, Abcam), vimentin mouse monoclonal antibody (1:1000, Cat# V5255, Sigma-Aldrich, St. Louis, MO, USA), and β-actin mouse monoclonal antibody (1:5000, Cat#A5316, Sigma-Aldrich). For secondary antibodies, ECL<sup>™</sup> HRP-conjugated anti-mouse or anti-rabbit IgG (GE Healthcare, Chicago, IL, USA) were used. For pull-down western experiments, HRP-conjugated anti-rabbit heavy chain (Jackson ImmunoResearch Labs, West Grove, PA, USA) was used.

Plasmid construction

For LincIN short hairpin RNAs (shRNAs), sense and antisense oligos were designed using the Whitehead Institute online tool (http://sirna.wi.mit.edu/) and synthesized by Integrated DNA Technologies (IDT) (Coralville, IA, USA). The oligos were then annealed prior to cloning into the Age I and EcoR I restriction enzyme sites of pMKO.1-GFP, which was purchased from Addgene (Cambridge, MA, USA). After screening for LincIN knockdown efficacy, two of the most efficient shRNA constructs were chosen from a total of seven shRNA designs (sequences listed in Additional file 1: Table S1). In addition, the full length of LincIN was synthesized by Genewiz, Inc. (Cambridge, MA, USA), and was cloned into the pRetroX-IRES-ZsGreen vector (Clontech, Mountain View, CA, USA) at the BamH I and Not I restriction enzyme sites.

Dicer-substrate siRNA transfection

Dicer-substrate small interfering RNAs (siRNAs) for LincIN were designed and synthesized from IDT. Sequences for siLincINA and siLincINB were as follows: GGAC AUUAUGCAAGGAGAUUGGCATC (sense), GAUGCCA UCUCCUUGCAUAUGUCCUU (antisense); and CAC
CCUGCCAGAUGUGUCUUGUCC (sense) and GGA ACAAGACACAUGGGCA GGUGUCC (antisense). Pre-designed NF90 siRNAs and scrambled controls (SC) were purchased from IDT. siRNAs were transfected into cells using Oligofectamine or Lipofectamine 3000 reagents (Life Technologies) according to the manufacturer’s instructions.

Wound closure assay, invasion, and cell cycle analysis
After breast cancer cells were cultured in a monolayer and reached 90–95% confluence, a scratch wound was carried out by creating a linear cell-free region using sterilized pipette tips as described previously [34]. The progress of cell migration into the scratch was photographed every 24 hours using an inverted fluorescence microscope. The images are further analyzed quantitatively using National Institutes of Health ImageJ software. Invasion assay was performed using the BD BioCoat™ Matrigel™ Invasion Chamber (BD Biosciences, Franklin Lakes, NJ, USA) following the manufacturer’s instructions. The invaded cells were stained with 1% crystal violet and examined under a light microscope. Cell cycle assay was done using the Nuclear-ID™ Red Cell Cycle Kit (Enzo Life Sciences, Farmingdale, NY, USA).

Mouse tail vein injection metastasis model and bioluminescent imaging analysis
All the animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at FCCC. Stable lines expressing empty green fluorescent protein (GFP) vector or LincIN shRNAs were generated using MDA-MB-231-Luc-D3H1 cells. To establish a lung metastasis model, 2 × 10^6 MDA-MB-231-Luc cells were injected intravenously (tail vein) into female SCID mice of 6–7 weeks old. Images were taken at multiple time points (days 1, 7, 14, 21, 28, and 43) after injections of tumor cells. Bioluminescence imaging of animals was performed using standard display methods (exposure time, 1–60s; binning 8; field of view 4; f/stop 1; open filter) on the IVIS™ Spectrum system (PerkinElmer, Waltham, MA, USA). Total photon flux (photons/sec) was determined from the region-of-interest (ROI) using Living-Image (Xenogen, Hopkinton, MA, USA) analysis software.

RNA-protein pull-down and mass spectrometry analysis
Full-length sense and antisense of LincIN or LincIN RNA fragments (1-320, 332-554, and 538-1031) were in vitro transcribed with the TranscriptAid T7 High Yield transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA) and labeled with biotin using the Pierce™ RNA-Protein Pull-Down Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. LincIN-associated proteins were eluted and resolved by gel electrophoresis followed by staining with the SilverQuest™ Silver Staining Kit (Life Technologies) or directly used for Western blotting. Protein bands of interest were excised, de-stained, and digested prior to analysis by LC-MS/MS using reverse phase capillary high-performance liquid chromatography (HPLC) with a Thermo Electron LTQ OrbiTrap XL mass spectrometer at The Wistar Institute.

RNA immunoprecipitation (RIP) and Immunoprecipitation (IP)
RIP experiments were performed using the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (EMD Millipore, Billerica, MA, USA) according to the manufacturer’s protocol. Briefly, fresh lysates from MDA-MB-231 cells were prepared using RIP lysis buffer containing a protease inhibitor cocktail and RNase buffer. Five μg of NF90 or control antibodies (anti-SNRNP70 and normal rabbit IgG) were captured by magnetic beads and incubated with 100 μL cell lysate for 8 h at 4 °C. The co-precipitated RNAs were extracted using protease K and phenol/chloroform precipitation. Precipitated RNAs and total RNAs (input controls) were treated with TURBO™ DNase (Life Technologies) prior to the reverse transcription with the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). Analysis of LincIN RIP signals were performed using a customized-designed TaqMan assay (Applied Biosystems) via real-time PCR. IP was performed using the Magnetic Dynabeads Kit (Thermo Fisher Scientific) according to the manufacturer’s manual.

Statistical analysis
The LIMMA (Linear Models for Microarray Data) methodology [35, 36] was used to identify differentially expressed intergenic lncRNAs between paired tumor and normal samples. The Benjamini-Hochberg method was used to adjust for multiple testing and to calculate the false discovery rate (FDR) for each lncRNA probe [37]. Computations were performed using the R statistical language and environment [38]. The Wilcoxon signed-rank test was used to compare differences between paired tumor and normal samples for RNA-ISH and TCGA data; and Kaplan-Meier survival curves were compared using log-rank tests. Kruskal-Wallis and Fisher’s exact tests were used to test the association between clinical variables and LincIN expression levels. In vitro data was analyzed using one-way analysis of variance (ANOVA) and Dunnett’s test to account for multiple post hoc comparisons or the two-sample t test. All tests
were two-sided and used a type I error of 5%. TCGA data was analyzed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA). If not mentioned specifically, all experiments were repeated in triplicate.

Results
Identification of a novel breast cancer-associated intergenic IncRNA, LincIN
To identify novel breast cancer-associated IncRNA candidates at intergenic regions, we employed a high-density SNP array-based approach by specifically probing intergenic regions to uncover IncRNA genes, whose expression was altered in breast tumors (Fig. 1a). To minimize the confounding effect from admixed stromal cells, we enriched the epithelial cell population and investigated their differential expression patterns between invasive ductal carcinoma (IDC) tissues and adjacent normal breast tissues (Additional file 1: Figure S1A).

As a result, we identified 26 intergenic IncRNA transcripts that are dysregulated in tumors \( |P < 0.005, \text{FDR} < 0.15, |\log_2 \text{(fold change)}| > 1 \). Among them, 14 IncRNAs (targeted by 22 SNP markers) were upregulated, and 12 IncRNAs (targeted by 16 SNP markers) were downregulated (Fig. 1b and Additional file 1: Table S2). One of the dysregulated intergenic IncRNAs, termed LincIN (GenBank access number: KX352723), is located at Chr10p11-12 and between two coding genes, ITGB1 and NRP1 (Fig. 1c). Notably, data from five IncRNA exon-targeting probes (kgp29833987, kgp21612648, kgp5242998, kgp21865691, and kgp391420) showed that LincIN is significantly upregulated in breast tumors in comparison to the normal components (\( \log_2 \text{FC} = 1.3-2.3 \) and \( P < 0.005 \)) (Fig. 1b and Additional file 1: Table S2). Further gene expression analysis by RT-qPCR demonstrated that LincIN is significantly upregulated in the majority of tumor HMEC lines in comparison to paired normal lines (8 out of 10, \( P < 0.05 \)) (Fig. 1d).

To characterize the full-length transcript of LincIN, we performed 5’ and 3’ rapid amplification of cDNA ends (RACE) and identified two spliced LincIN RNA variants (Fig. 1e). Sequence analysis of LincIN transcripts revealed that LincIN RNA utilizes two poly(A) sites to generate a short transcript (833 bp) and a longer transcript (1031 bp) (Fig. 1e). The expression of the longer LincIN variant appears to be more abundant and thus is the focus of our functional analysis. In addition, cellular fractionation analysis revealed that LincIN is distributed in both the nucleus and the cytoplasm (Additional file 1: Figure S2). Lastly, the 3’ end of LincIN appears to be polyadenylated since LincIN is clearly detected in poly(A)-enriched RNA fractions (Additional file 1: Figure S2).

Based on a BLASTX analysis of all possible reading frames identified by the open reading frame (ORF) finder from the NCBI and ATGpr (http://atgpr.dbcls.jp/), LincIN lacks the potential to encode any recognizable protein domains. As described previously [19], we further examined the coding potential of LincIN using a bioinformatics tool, PhyloCSF, a comparative genomics method for distinguishing protein-coding and non-coding regions based on their evolutionary signatures characteristic to alignments of conserved coding regions [39]. This analysis confirmed the low coding potential of LincIN, which receives a maximum smoothed codon substitution frequency (CSF) value similar to other well-characterized IncRNAs (Additional file 1: Figure S3). These findings established LincIN as a new IncRNA, and we next investigated its role in breast cancer development.

LincIN is overexpressed in advanced human breast tumors and is a promising breast cancer prognostic biomarker
Previously, one genome-wide association study (GWAS) identified a breast cancer survival variant, rs11591508 \( (P = 3.27 \times 10^{-6}, \text{hazard ratio} = 2.41-3.29) \), which is located at the LincIN locus [40] (Fig. 1c). This finding suggested that LincIN may be a biomarker for breast cancer prognosis. Therefore, the expression of LincIN in breast tissues was evaluated initially by RNA in situ hybridization (RNAscope®) utilizing an in-house TMA, which contained a panel of breast normal (36) and tumor (103) specimens. After inspecting RNA quality with the POLR2 and dapB staining, 20 samples with RNA degradation were excluded, which left the cohort with 88 tumors and 31 normal specimens including 27 tumor/normal pairs for final analysis. Figure 2a shows the representative RNAscope® ISH images with different LincIN staining levels. Among all the specimens, LincIN exerts positive staining in approximately 72% of the breast tumor tissues (63 out of 88, score ranging from 1–2) while only approximately 29% of the normal tissues show positive LincIN expression (9 out of 31, score 1–2; \( P < 0.001 \)) (Fig. 2b). Furthermore, LincIN levels are significantly higher in tumors comparing to those in matched adjacent normal tissues \( (P < 0.001) \) by Wilcoxon test (Fig. 2c). To further examine the potential value of LincIN as a breast cancer prognostic biomarker, we used a larger breast cohort retrieved from the TCGA Data Portal. After initial exclusions for replication and probe values of zero, there were expression data for 752 tumor specimens and 98 normal specimens. Among them, 88 normal samples were collected from matched breast tumor. Consistently, quantification of LincIN levels demonstrated significantly higher expression levels of LincIN in tumors versus matched adjacent normal tissues \( (n = 88) \) (4.28 vs.1.96, \( P = 0.018 \)) (Fig. 2d). Notably, the levels of LincIN in breast tumors increase significantly with the pathologic stages defined by the American Joint Committee on...
Cancer (AJCC) or the tumor size (Table 1). For overall survival analysis, patients with follow-up days = 0 and pathologic tumor stage stated as "not available" were excluded, and 738 patients were included in the final survival analyses. Because of the skewed distribution of LincIN, we used categories based on LincIN levels rather than percentiles, with ≤1, >1–5, >5–10, and >10–83 as the initial groups. Based on similarities in survival in the higher LincIN groups, the upper categories were combined into LincIN > 1. The survival analysis showed that patients expressing high levels of LincIN (>1.0) have worse survival outcomes (P = 0.044 and P = 0.011 after adjust for age) (Fig. 2e).
Expression of LincIN in clinical samples. 

**a** LincIN expression was evaluated by RNAcope® ISH analysis on FFPE tissue microarrays (TMA) containing normal breast tissue and invasive breast carcinoma. To exclude low-quality tissue specimens due to potential RNA degradation, we simultaneously performed RNAScope® ISH experiments in positive (POLR2) and negative (dapB) controls in serial TMA sections.

**b** Analysis of RNA-ISH scores in 88 tumor and 31 normal samples using the two-sample Wilcoxon test.

**c** Analysis of RNA ISH scores in 27 tumor and normal paired samples using the two-sample Wilcoxon test.

**d** LincIN RNAseq expression data (RPKM value) for 88 normal-tumor pairs were retrieved from TCGA. The Wilcoxon signed-rank test was used for the comparison of matched pairs.

**e** Overall survival (OS) from initial pathologic diagnosis was estimated using Kaplan-Meier methods, based on vital status and “days to death” or “days to last follow-up”. Individuals who were still alive at the time of last the follow-up were censored.

Fig. 2 Expression of LincIN in clinical samples. a LincIN expression was evaluated by RNAcope® ISH analysis on FFPE tissue microarrays (TMA) containing normal breast tissue and invasive breast carcinoma. To exclude low-quality tissue specimens due to potential RNA degradation, we simultaneously performed RNAScope® ISH experiments in positive (POLR2) and negative (dapB) controls in serial TMA sections. b Analysis of RNA-ISH scores in 88 tumor and 31 normal samples using the two-sample Wilcoxon test. c Analysis of RNA ISH scores in 27 tumor and normal paired samples using the two-sample Wilcoxon test. d LincIN RNAseq expression data (RPKM value) for 88 normal-tumor pairs were retrieved from TCGA. The Wilcoxon signed-rank test was used for the comparison of matched pairs. e Overall survival (OS) from initial pathologic diagnosis was estimated using Kaplan-Meier methods, based on vital status and “days to death” or “days to last follow-up”. Individuals who were still alive at the time of last the follow-up were censored.
Table 1 TCGA, Comparison of LincIN expression values by pathologic stages

| Pathologic stage (AJCC) | N     | Median (1st, 3rd quartiles) | Mean (Std Dev) | P-value* |
|------------------------|-------|-----------------------------|----------------|---------|
| I (incl stage I, IA, IB) | 125   | 0.39 (0.22, 1.76)          | 2.06 (4.83)    | 0.021   |
| II (incl stage II, IIA, IIB) | 432   | 0.54 (0.25, 3.75)          | 3.85 (8.34)    |         |
| III (incl stage III, IIIA, IIIB, IIIC) | 165   | 0.68 (0.23, 5.09)          | 3.92 (6.32)    |         |
| IV (incl stage IV) | 14    | 1.44 (0.28, 4.15)          | 4.33 (7.56)    |         |

Pathologic stage (tumor size)

| T1, <2 cm (incl T1,T1a,T1b,T1c) | 199   | 0.40 (0.22, 3.36)          | 2.95 (6.85)    | 0.0038  |
| T2, 2-5 cm (incl T2, T2b) | 443   | 0.54 (0.25, 4.04)          | 3.63 (7.10)    |         |
| T3, >5 cm (incl T3) | 80    | 0.47 (0.21, 2.41)          | 3.76 (9.65)    |         |
| T4 (incl T4,T4b,T4d) | 28    | 2.04 (0.63, 9.64)          | 6.02 (7.48)    |         |

*P value is from Kruskal-Wallis test to compare LincIN distributions within pathologic stages defined by AJCC or tumor size. This nonparametric test was used instead of one-way ANOVA due to the skewed distribution of the LincIN expression values. The samples with pathologic information stated as ‘not available’ were excluded from data analysis.

Role of LincIN in breast cancer cell invasion and metastasis

As LincIN is frequently overexpressed in advanced breast tumors, we sought to explore the functional roles of LincIN in breast cancer progression-metastasis. Examining LincIN expression levels in a panel of 12 breast cell lines showed that LincIN is overexpressed up to 40-fold in highly metastatic MDA-MB-231 cells (ER-/PR-/HER2-), versus immortalized but non-transformed MCF10A cells (P < 0.001) (Additional file 1: Figure S4). We next evaluated the impact of LincIN loss on cell migration and invasion in MDA-MB-231 cells. Suppression of LincIN by RNA interference (RNAi) leads to an approximately 40–50% reduction of cell invasion compared to the control group (P < 0.05) (Fig. 3a). This inhibitory effect is even more profound in HCC1937 cells (high expression of LincIN, ER-/PR-/HER2-), where about 50–80% reduction is observed as the result of silencing LincIN (P < 0.01) (Fig. 3b). Knockdown of LincIN in MDA-MB-231 cells also significantly decreases cell migration about approximately 30% compared to those transfected with vector in the wound closure assay (Additional file 1: Figure S5A). In contrast, overexpression of LincIN in MCF10A/Dcis cells (non-invasive breast cancer cells and low expression of LincIN) tended to accelerate cell migration (P < 0.05) (Additional file 1: Figure S5B). We also examined the role of LincIN in cell proliferation. As shown in Additional file 1: Figure SSC, overexpression of LincIN in MCF-10A and MCF10A/Dcis cells increases cell proliferation moderately (P < 0.05). However, downregulation of LincIN in MDA-MB-231-luc cells has no significant effects on cell proliferation. Taken together, these data suggest that LincIN plays a role in breast tumor cell migration and invasion in vitro, while the effects of LincIN on cell proliferation may be cell type-specific.

Next, we injected MDA-MB-231luc cells via the tail vein into severely combined immunodeficiency (SCID) mice to test a possible role of LincIN in cancer cell metastasis. Strikingly, we found that knockdown of LincIN significantly decreases lung metastases compared to those in the vector control, as evaluated by bioluminescent signals (P < 0.005–0.05) (Fig. 3c and d). Furthermore, quantification of scanned images of whole lung tissues showed a significant decrease (approximately 60%) in the metastatic area in mice receiving shRNA-treated cells as compared to those of the vector control (P < 0.05) (Fig. 3e). In addition, we observed variations of the inhibitory effects on lung metastasis between shRNA1 and shRNA2 treatments. To exclude potential off-target effects, we performed transcriptome analysis in MDA-MB-231 cells treated with vector control, shRNA1 or shRNA2 in duplicate. As a result, we found 173 and 321 differentially expressed genes for shRNA1 and shRNA2 treatments, respectively, in comparison to the vector control (P < 0.001, Additional file 1: Table S3). Among them, 122 genes are overlapped (Additional file 1: Figure S6A), and the values of Log2 (FC) of overlapping “hits” are significantly correlated between the two shRNA groups (R2 = 0.9596, P < 0.0001 by Spearman’s rho test, Additional file 1: Figure S6B). Furthermore, biological process analysis of differentially expressed genes by Ingenuity Pathway Analysis (IPA) showed that over 97% of the identified pathways are overlapped (74 out of 75 or 76 for shRNA1 or shRNA2 treatments, respectively (P < 0.01, Additional file 1: Figure S6C and Additional file 1: Table S4). These results suggest that the variations from different shRNA effects are not accounted for by off-target effects. Notably, the very top cellular functions targeted by both shRNAs was cellular movement (P < 1.05 × 10^{-6} approximately 5.27 × 10^{-3}), providing molecular insight for the role of LincIN in tumor cell invasion through the regulation of...
Fig. 3 (See legend on next page.)

**Cellular functions by top hits from shRNA treatments (P<0.01)**
gene transcription (Fig. 3f). Collectively, our results suggest that LincIN is involved in breast cancer cell invasion in vivo and knockdown of LincIN in breast cancer cells may effectively inhibit the metastatic processes.

LincIN interacts with the RNA-binding protein NF90

To identify LincIN-interacting protein partner(s) that may contribute to its function in breast cancer development, we used in vitro transcribed biotin-labeled full-length LincIN for pull-down experiments followed with protein identification by mass spectrometry (MS) (Fig. 4a). The spectra counts were used to determine which proteins were unique/more abundant in a particular condition/gel band. Among the proteins identified by MS (Fig. 4b), NF90/ILF3 was the most abundant LincIN-binding partner. NF45/ILF2, which dimerizes with NF90 to form a functional complex, was also identified by MS as a LincIN-interacting protein. The LincIN-NF90 interaction
Importantly, under the condition of NF90 knockdown, the LincIN RNA required for NF90 binding, in vitro transcribed biotin-labeled truncated LincIN transcripts were also prepared for RNA pull-down experiments (Fig. 4d, left panel). Transcripts that contained the 5’ region of LincIN exhibited the strongest binding to NF90, while weaker binding was observed in the 3’ and center regions (Fig. 4d, right panel). We further confirmed the interaction between LincIN and NF90 by performing RNA immunoprecipitation (RIP) with an antibody against NF90. As shown in Fig. 4e, LincIN RNA was enriched by approximately 40-fold in NF90 antibody precipitates. Altogether, RNA-pull-down and RIP experiments provided reciprocal evidence that LincIN directly interacts with NF90.

**LincIN regulates p21 protein expression at the translational level partially though the interactions with NF90**

Recent studies showed that NF90 is multifunctional in cells, including repressing p21 protein expression in cancer cells [28]. We next examined if LincIN plays a role in the NF90-mediated p21 pathway. Overexpression of LincIN in MCF10A cells diminishes p21 protein expression by approximately 40% (left panel, Fig. 5a). Reciprocally, the level of p21 protein is consistently induced (approximately twofold) in LincIN knockdown groups compared to scrambled control (right panel, Fig. 5a). In contrast with altered protein expression, static p21 mRNA levels remain unchanged in both LincIN overexpression and knockdown experiments (Fig. 5b), suggesting that LincIN regulates p21 at the translational level. Moreover, loss of LincIN results in increased G1/G0 arrest (P < 0.05) (Fig. 5c and d), which is a typical phenotype associated with the elevated expression of p21. In addition, we have evaluated the p21 level in the mouse lung metastasis colonies by immunohistochemistry (IHC), and the nuclear p21 levels are higher in the metastasis colonies from the LincIN shRNA knockdown group compared to those tissues from shRNA control group (P < 0.05, Additional file 1: Figure S7 and Additional file 1: Table S5). This finding suggests that upregulation of nuclear p21 by LincIN knockdown may be associated with less aggressive phenotype in our metastasis model.

Since recent studies showed that NF90 may regulate p21 protein expression at the translational level via binding its 3’ untranslated region (UTR) [29], we sought to determine if LincIN mediates p21 protein expression via NF90. We knocked down LincIN, NF90, or both using siRNAs and measured p21 expression by Western blotting. As expected, knockdown of NF90 upregulates p21 protein levels (approximately twofold) (right panel, Fig. 5e). Importantly, under the condition of NF90 knockdown, the effects of siLincIN on elevating p21 expression (evaluated by the ratio of siLincIN + siNF90/siNF90) in HeLa cells is decreased in comparison to the cells treated with siLincIN alone (the ratio of siLincIN/SC) (P < 0.05) (right panel, Fig. 5e). Furthermore, LincIN overexpression-induced p21 inhibition is also partially diminished by NF90 silencing in MCF-10A cells (Fig. 5f). Knockdown or overexpression of LincIN had no significant effects on the expression of NF90 (Fig. 5e and f). Taken together, these results suggest that LincIN may cooperate with NF90 to inhibit p21 translation.

**Discussion**

Functional characterization of individual lncRNAs has greatly extended our understanding of the complexity of the functional RNAs, which have been previously under-appreciated, and it has also raised interest in determining underlying mechanisms. In the present study, we used high-density SNP arrays to explore the transcriptome of intergenic lncRNAs in breast cancer. We identified a new metastasis-associated lncRNA, LincIN (Fig. 1). High levels of LincIN expression are significantly associated with advanced breast cancer, and analysis of a large TCGA cohort suggested that LincIN is a promising prognostic biomarker for breast cancer (Fig. 2 and Table 1). Our in vitro and in vivo experiments demonstrated that LincIN may play an important role in tumor cell invasion and metastasis, and these findings are consistent with the results from transcriptome analysis in LincIN-knockdown cells (Fig. 3). We also identified a LincIN-binding protein, NF90, through which LincIN mediates p21 protein expression and cell cycle (Figs. 4 and 5). Our findings delineated a functional role of LincIN in breast tumor progression-metastasis, and mechanistically uncovered that it may regulate gene expression at both the transcriptional and translational levels (Fig. 6).

LncRNAs exhibit more tissue-, cell-type- and disease-specific patterns of expression [41], and this feature makes them a potentially precise biomarker for cancer diagnosis or prognosis. LncRNAs, thereby, are emerging as a new class of biomarkers for cancer, particularly for the later stage of cancer progression [12, 42, 43]. However, the potential for a majority of lncRNAs as biomarkers has not been fully explored in breast cancer. Here, we demonstrated that LincIN levels are consistently higher in tumors compared to those in adjacent normal tissues by evaluating two independent sample sets collected from the FCCC Biosample Repository and a breast cancer TCGA study (Fig. 2). Importantly, high levels of LincIN in breast tumors are correlated with advanced pathologic stages and a worse survival outcome, suggesting that LincIN is a promising prognostic biomarker for breast cancer and likely plays a functional role in breast tumor progression/metastasis.
A number of lncRNAs have been associated with breast cancer development. *HOTAIR*, the first lncRNA implicated in breast cancer, interacts with the PRC2 complex and LSD1 and drives transcriptional repression; overexpression of *HOTAIR* causes a global repression of tumor suppressors, which promotes breast cancer metastasis [7]. Oncogenic FAL1 binds and stabilizes epigenetic repressor BMI1, resulting in suppression of gene transcription, and then to malignant transformation and breast tumor growth [8]. NKILA inhibits breast cancer metastasis, specifically through binding and masking the IKB phosphorylation motif, and thus, preventing the activation of the NF-κB pathway [9]. Here, we demonstrate a critical role for *LincIN* in controlling breast cancer metastasis. Knockdown of *LincIN* in breast cancer cells diminished tumor cell invasion in vitro and it also

---

**Fig. 5** *LincIN* interacts with NF90 in the translation regulation of p21 expression. **a** Left panel: Western blot of p21 and beta-actin in vector and *LincIN* overexpressed MCF10A cells. Right panel: Western blot of p21, beta-actin or NF90, in SC and *LincIN* knockdown groups of HeLa cells. **b** RT-qPCR results of p21 in *LincIN* overexpression and vector control groups in MCF10A cells (left). RT-qPCR analysis of *LincIN* knockdown versus scrambled control in HeLa cells (right). **c** and **d** Cell cycle profiles and quantification of MDA-MB-231 cells treated with SC or *LincIN* siRNAs for 48 h (n = 3). Data was analyzed using one-way ANOVA and t test (\( ^*P < 0.01 \), and \( ^{**}P < 0.05 \)). **e** Right panel: MCF10A cells (vector or *LincIN*) were stably transfected with siRNA targeting NF90 or scrambled control. Cell lysates were collected at 48 h after transfection. Left panel: ratios of p21 expression in *LincIN*-overexpression to vector control cells (right panel) (\( ^*P < 0.05 \); t test). **f** Right panel: Western blot of NF90, NF45, and p21 in HeLa cells treated with SC, *LincIN* or NF90 siRNA alone or in combination. Cell lysates were collected at 48 h after transfection, repeated in triplicate. Left panel: ratios of p21 expression in si*LincIN*-transfected to SC control cells (\( ^*P < 0.05 \); t test).
may interact with specific partners, such as LincIN, be a nonspecific double-stranded RNA-binding protein, These results suggest that NF90, previously believed to other RNA-binding proteins, such as TARBP2 [44, 45]. Such a bidirectional role has also been reported for gene expression that is biological milieu-dependent. p21 could also be upregulated in NF90-silenced viral-mice [29]. However, subsequent findings showed that p21 expression in NF90-silenced viral-transfected HeLa cells [28], which were consistent with our data reported here. These findings suggest a bidirectional role of RNA-binding protein NF90 in regulating gene expression that is biological milieu-dependent. Such a bidirectional role has also been reported for other RNA-binding proteins, such as TARBP2 [44, 45]. These results suggest that NF90, previously believed to be a nonspecific double-stranded RNA-binding protein, may interact with specific partners, such as LincIN, and exert a specific functional role in certain biological milieu. Vumbaca et al. demonstrated that knockdown of NF90 decreased tumorigenesis and angiogenesis in an orthotopic breast tumor xenograft model [46]. As our results suggest, LincIN mediates protein translation (e.g., p21) through its interactions with NF90 (Fig. 6), and our IHC experiments show that the downregulation of LincIN knockdown significantly increases the level of nuclear p21 (P < 0.05, Additional file 1: Table S5 and Additional file 1: Figure S7B). Although the role of p21 in tumor invasion and metastasis is still not fully explored, nuclear p21 but not cytoplasmic p21 has favorable prognostic outcomes in breast and other cancers [47–49]. Our results suggest that the upregulation of nuclear p21 by LincIN knockdown may be associated with less aggressive metastasis phenotypes. Future studies examining how LincIN mediates tumor progression and metastasis through the NF90-mediated p21 pathway are warranted.

In our current study, we have demonstrated that LincIN is significantly upregulated in tumors versus normal samples. Importantly, knockdown of LincIN in breast cancer cells diminishes cancer cell migration and invasion in vitro, and reduced lung metastasis in a mouse tail vein injection model. These findings make LincIN a promising druggable target for preventing/treating breast cancer metastasis. The development of lncRNAs as a novel class of drug targets for breast cancer treatment is still at the very early stage, but these non-coding RNAs may hold the promise for new drug discovery [50]. Importantly, the identification of NF90, one of the functional LincIN-binding partners, provides an alternative strategy for drug development by targeting LincIN-NF90 interactions. As RNA-protein interactions (RPIs) are commonly present in functional RNAs, targeting RPIs using antisense oligos could provide a more efficient and specific approach than conventional RNAi technologies [51].

Conclusions

Overall, we identified and characterized a novel breast cancer-associated IncRNA, LincIN, by evaluating the IncRNA transcriptome in paired normal versus tumor samples. Our demonstration of a correlation between breast patient survival outcomes and LincIN expression highlights its potential role as a prognostic biomarker. Our functional studies have established a potential role for LincIN in breast cancer progression/metastasis and revealed that its IncRNA-protein (e.g., NF90) interactions can be a novel approach for the regulation of protein expression. Since silencing of LincIN effectively reduced cancer cell metastasis, we propose that LincIN could potentially be a promising therapeutic target for the inhibition of progression of metastatic breast cancer.
Additional file

Additional file 1: Supplementary figures and tables. (ZIP 4.69 mb)

Abbreviations

AJCC: American Joint Committee on Cancer; ANOVA: Analysis of variance; ATCC: American Type Culture Collection; CF: Codon substitution frequency; DNA: Deoxyribonucleic acid; FCCC: Fox Chase Cancer Center; FDA: Food and Drug Administration; FDR: False discovery rate; FFPE: Formalin-fixed, paraffin-embedded; GFP: Green fluorescent protein; GWAS: Genome-wide association studies; H&E: Hematoxylin and eosin stain; HMEC: Human mammary epithelial cells; HPLC: High-performance liquid chromatography; IDC: Invasive ductal carcinoma; IHC: Immunohistochemistry; IPA: Ingenuity® Pathway Analysis; IRB: Institutional Review Board; LIMMA: Linear Models for Microarray; LincRNA: Long intergenic non-coding RNA between ITGB1 and NRPI; IncRNA: Long non-coding RNA; MS: Mass spectrometry; NC: Negative control; NF90: Nuclear factor 90; PC: Positive control; pQPCR: Quantitative polymerase chain reaction; RIP: RNA immunoprecipitation; RLM-RACE: RNA lige-mediated rapid amplification of cDNA ends; RNA: Ribonucleic acid; RNA ISH: RNA in situ hybridization; RNAi: RNA interference; RQ: Region-of-interest; RPL: RNA-protein interactions; RPMA: Reads per kilobase million; RT-qPCR: Reverse transcription and quantitative PCR; SC: siRNA control; SCID: Severe combined immunodeficiency; shRNA: short hairpin RNA; siRNA: small interfering RNA; SNP: Single-nucleotide polymorphism; TCGA: The Cancer Genome Atlas; TMA: Tissue microarray; UTR: Untranslated region

Acknowledgements

We are grateful to Drs. D. West, W. Kruger, M. Clapper and other faculty members from FCCC, and Dr. J. Anderson from University of North Carolina at Chapel Hill for their insightful comments on the manuscript. The authors also thank the following core facilities at FCCC for their help: BioSample Repository, Genomics, High Throughput, Laboratory Animal and Small Animal Imaging, Histopathology, and the Biostatistics and Bioinformatics.

Funding

This work was kindly supported by Susan G. Komen for the Cure (KG100274 to XC), NIH CA186853 (to XC), the Elieen Stein Jacoby Fund (to XC), FCCC (P30-CA06927), as well as an appropriation from the State of Pennsylvania. No potential conflicts of interest were disclosed.

Availability of data and materials

Microarray from this study has been submitted to the NCBI Gene Expression Omnibus (GEO), under accession number GSE9214 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9214). The RNA sequence of LincRNA has been submitted to GenBank (access number: KCGS5723).

Authors’ contributions

ZJ carried out the molecular genetic studies, participated in ReadChip data analysis, and drafted the manuscript. CS carried out the cell culture experiments, performed the immunobassys, and helped to revise the manuscript. Y2, KD, and KR participated in the design of the study, performed the statistical analysis, and helped to revise the manuscript. KC and YL participated in the mouse experiments and helped to revise the manuscript. MD participated in the design of the study and helped to revise the manuscript. XC conceived of the study, and participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Paired tissue specimens from patients diagnosed with invasive breast cancer were collected under the approval (#11-871) of the Institutional Review Board (IRB) at Fox Chase Cancer Center (FCCC). Informed written consent was obtained from all participants prior to participation.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Cancer Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 2Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 3Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 4Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 5Present Address: Department of Medicine, Irving Cancer Research Center, Columbia University, New York, NY 10032, USA. 6Present Address: The Third Xiangya Hospital of Central South University, Changsha, China.

Received: 10 July 2016 Accepted: 5 May 2017

Published online: 30 May 2017

References

1. Gabbili MN, Trapnell C, Goff L, Kozol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25:1915–27.
2. Derrien T, Johnson R, Bussotti G, Tarazona S, Djebali S, Tilgner H,Guex M, Martin D, Murchison T, Klose K, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
3. Guttman M, Amit I, Barber G, French C, Lin MF, Feldser D, Huarte M, Zok O, Carey BW, Cassady JP, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223–7.
4. Batista PJ, Chang HY. Long non-coding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–307.
5. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(7):21–33.
6. Li L, Chang HY. Physiological roles of long non-coding RNAs: insight from knockout mice. Trends Cell Biol. 2014;24(10):594–602.
7. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani P, Rinn JL, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7301):542–8.
8. Hu X, Feng Y, Zhang D, Zhao Shijai D, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang L-P, et al. A functional genomic approach identifies FAL1 as an oncogenic long non-coding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014;26:344–57.
9. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lu X, Lin L, Yao H, Su X, Li D, et al. A cytoplasmic NF-κB interacting long non-coding RNA blocks NF-κB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27:370–81.
10. Silva JM, Boczek NJ, Beers MW, Xa S, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA. 2011;18:496–505.
11. Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, Park PK, Qin L, Wei Y, Hawke DH, et al. IncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell. 2014;159:1110–25.
12. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell. 2015;28(4):529–40.
13. Ulltisvy L, Bartel DP. IncRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46.
14. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB. An architectural role for a nuclear noncoding RNA: NEAT1 mRNA is essential for the structure of paraspeckles. Mol Cell. 2009;33(6):717–26.
15. Hacisuleyman E, Goff LA, Trapnell C, Williams A, Henao-Mejia J, Sun L, McClanahan P, Hendrickson DG, Sauvageau M, Kelley DR, et al. Topological organization of multichromosomal regions by the long intergenic noncoding RNA Fire. Nat Struct Mol Biol. 2014;21(2):198–206.
16. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20:300–7.
17. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagian BG, Morgan TE, Finch CE, St Laurent G, Kenny PJ, Walshledt C. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14:723–30.
18. Gong C, Maquat LE. IncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3′ UTRs via Alu elements. Nature. 2011;470:286–8.
19. Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILO proteins. Cell. 2016;164(4):59–80.
20. Yoon JH, Abdelmohsen K, Srikanth S, Yang X, Martindale JL, De S, Huarte M, Zhang M, Becker KG, Gorospe M. LincRNA-p21 Suppresses Target mRNA Translation. Mol Cell. 2012;47:468–55.

21. Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, Jiang Z, Xu J, Liu Q, Cao X. The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation. Science. 2014;344:310–3.

22. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9:703–19.

23. Kao PN, Chen L, Brock G, Ng J, Kenny J, Smith AJ, Corbey H, Cloning and expression of cyclophilin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. J Biol Chem. 1994;269:20691–9.

24. Castella S, Bernard R, Corme F, Fradin A, Larcher JC. IF3 and NF90 functions in RNA Biology. Wiley Interdiscip Rev RNA. 2015;6(2):243–56.

25. Masuda K, Kisuwan Y, Nishida K, Rokutan K, Imoto I. NF90 in posttranscriptional gene regulation and microRNA biogenesis. Int J Mol Sci. 2013;14(8):17111–21.

26. Jiang W, Huang H, Ding L, Zhi P, Sayin H, Ji G, Zuo J, Han D, Pan Y, Ding D, et al. Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 2015;34(4):4660–70.

27. Pullmann R, Jr HH, Abdelmohsen K, Lal A, Martindale JL, Yang X, Gorospe M. Analysis of turnover and translation regulatory RNA-binding protein expression through binding to cognate mRNAs. Mol Cell Biol. 2007;27(18):6265–78.

28. Shamanna R, Hoque M, Peery T, Mathews MB. Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical cancer cells. Oncogene. 2013;32:5176–85.

29. Shi L, Zhao G, Qiu D, Godfrey WR, Vogel H, Rand A, Hu H, Kao PN. NF90 regulates cell cycle exit and terminal myogenic differentiation by direct binding to the 3′-untranslated region of MyoD and p21 WAF1/CIP1 mRNAs. J Biol Chem. 2005;280:18981–9.

30. Gao C, Devarajam K, Zhou Y, Slater CM, Daly MB, Chen X. Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome. BMC Genomics. 2012;13:570.

31. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

32. Simon R, Lam A, Li MC, Ngn M, Menzenes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007;3:11–7.

33. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Herstand JC, Young E, Mulkapadhyay P, Yeh HW, Allred DC, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11(5):R66.

34. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329–33.

35. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.

36. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article5.

37. Benjamin J, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289–300.

38. R Development Core Team. In: R: a language and environment for statistical computing, editor. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2014.

39. Lin MF, Jungreis I, Kells M. PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions. Bioinformatics. 2011;27(1):275–282.

40. Azzato EM, Pharoah DP, Harrington P, Easton DF, Greenberg D, Caporaso NE, Chanock SJ, Hoover RN, Thomas G, Hunter DJ, et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomark Prev. 2010;19:1140–3.

41. Brunnler AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R, Montgomery K, Varma S, Gilks T, Guo X, et al. Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol. 2012;13:R75.

42. Yang QQ, Deng YF. Long non-coding RNAs as novel biomarkers and therapeutic targets in head and neck cancers. Int J Clin Exp Pathol. 2014;7(4):1286–92.

43. Yarmishyn AA, Kurochkin IV. Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet. 2015;6:145.